Hyundai ADM Bio Inc. (KOSDAQ:187660)

-8.45% (1Y)

Market Cap	61.36B
Revenue (ttm)	9.74B
Net Income (ttm)	-20.10B
Shares Out	42.29M
EPS (ttm)	-475.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	172,961
Average Volume	282,793
Open	1,423.00
Previous Close	1,421.00
Day's Range	1,400.00 - 1,470.00
52-Week Range	1,250.00 - 3,375.00
Beta	0.99
RSI	41.38
Earnings Date	May 14, 2025

About Hyundai ADM Bio

Hyundai ADM Bio Inc., a contract research organization, provides clinical services in Asia. It offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. The company also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. In addition, it develops, manufactures, and sells med...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 160
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187660

Financial Performance

In 2024, Hyundai ADM Bio's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.